Stay updated on PD-1 and NK Immunotherapy Combo in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the PD-1 and NK Immunotherapy Combo in Solid Tumors Clinical Trial page.

Latest updates to the PD-1 and NK Immunotherapy Combo in Solid Tumors Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page footer shows a new revision number (v3.6.3) replacing the previous v3.6.2, indicating a small maintenance update that does not affect displayed information or user interaction.SummaryDifference0.1%

- Check14 days agoChange DetectedFooter now displays Revision: v3.6.2 instead of v3.6.0, signaling a software version update for the page. This is a metadata/UI label change rather than a modification to the study details or content.SummaryDifference0.1%

- Check29 days agoChange DetectedRecruitment status now shows the study is no longer enrolling participants, indicating enrollment is closed; the page also adds new user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment header along with a revision note to v3.6.0.SummaryDifference0.5%

- Check36 days agoChange DetectedThe page revision label updated from v3.5.4 to v3.5.5, indicating a newer page version; no study data or content changes are introduced.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page revision label has been updated to v3.5.4, replacing the previous v3.5.3 and signaling a small update to the page’s documentation/metadata.SummaryDifference0.1%

- Check78 days agoChange DetectedA page revision identifier was updated from **v3.5.2** to **v3.5.3**, reflecting an update to the site/version rather than any change to the clinical trial information.SummaryDifference0.1%

Stay in the know with updates to PD-1 and NK Immunotherapy Combo in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-1 and NK Immunotherapy Combo in Solid Tumors Clinical Trial page.